zollinger-ellison%20syndrome
ZOLLINGER-ELLISON SYNDROME
Zollinger-Ellison syndrome (ZES) is a disease entity which refers to the triad of severe peptic ulcer disease (PUD), gastric acid hypersecretion and non-beta cell gastrin-secreting tumor primarily of the pancreas and duodenum (gastrinoma).
Approximately two-thirds of patients have sporadic ZES while the rest is part of multiple endocrine neoplasia type 1.
ZES should be considered in the differential diagnoses of patients who present with abdominal pain, malabsorption and chronic watery diarrhea.
A high index of clinical awareness is necessary to correctly diagnose ZES.

Zollinger-Ellison Syndrome Drug Information

Drug Information

Indication: Peptic ulcer disease associated w/ H pylori.

Indication: Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated ...

Indication: Healing & maintenance of erosive or ulcerative GERD. Healing of duodenal ulcers. Pathological hypersecreto...

Indication: Active duodenal, benign gastric, stomal & recurrent ulceration, persistent dyspeptic symptoms w/ or w/o ul...

Indication: Peptic ulcer associated w/ H pylori.

Indication: Reflux disease & associated symptoms. Prevention of gastroduodenal ulcers induced by NSAIDs in patients at...

Indication: 20 mg: Mild GERD & associated symptoms eg, heartburn, acid regurgitation, pain on swallowing. Long-term ma...

Dosage: Duodenal & benign gastric ulcers 20 mg once daily for 4-8 wk. Dose may be increased to 40 mg once daily in

Indication: Benign gastric & duodenal ulcer, GERD, Zollinger-Ellison syndrome, H pylori eradication.

1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.